Biotech News

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Phathom Pharmaceuticals (PHAT)Phathom Pharmaceuticals2026-06-25 13:46 ESTClinical readout

This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE Topline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026 FLORHAM PARK, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc.

Open original release

Related news

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance (Corrected)

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

View all latest news

Phathom Pharmaceuticals

Phathom Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

PHATPhathom Pharmaceuticals2026-06-26 12:02 EST

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

PHATPhathom Pharmaceuticals2026-06-26 12:02 EST

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

PHATPhathom Pharmaceuticals2026-06-26 12:02 EST

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

PHATPhathom Pharmaceuticals2026-06-26 12:02 EST

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

PHATPhathom Pharmaceuticals2026-06-26 12:02 EST

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States